TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05076448

Intervention type: PROCEDURE
Intervention: Gonadal veins resection
Description: Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected.

Intervention type: PROCEDURE
Intervention: Gonadal vein embolization with coils
Description: Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm.

Intervention type: PROCEDURE
Intervention: Endovascular stenting of the common iliac vein (CIV)
Description: After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed.
Study: NCT05283694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via prepared syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via prepared syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via syringe pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Subcutaneous Injection via syringe pump
Study: NCT03837977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Irinotecan
Description: Arm I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Arm I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Arm I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm II
Study: NCT01577979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminder/Recall
Description: Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Preference
Description: Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
Study: NCT03467243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training
Description: CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: TAU is when Veterans continue to receive their usual care.
Study: NCT03656562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: 150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VAY736
Description: 150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
Study: NCT01028014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg by mouth daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Imipramine 25mg daily by mouth for 2 weeks
Study: NCT03656562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VAY736 Placebo
Description: solution for injection; 0 mg/mL administered as 2 mL s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: 150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CFZ533
Description: 150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CFZ533 Placebo
Description: Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
Study: NCT04014608

Intervention type: OTHER
Intervention: Standard Practice to Prevent Hospital Onset CDI
Description: Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.

Intervention type: OTHER
Intervention: Standard Practice to Prevent Hospital Onset CDI
Description: Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
Study: NCT01003899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib (BIBW 2992)
Description: afatinib (BIBW 2992) po QD
Study: NCT00781209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation plus Stereotactic Radiosurgery
Description: Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy.
Study: NCT01045629

Intervention type: OTHER
Intervention: Consent form education
Description: Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
Study: NCT00963365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD6765
Description: Single oral dose and single IV infusion of AZD6765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD6765
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
Study: NCT02469493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture (Huatuo)
Description: The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
Study: NCT01640522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Collaborative care intervention to manage cancer-related symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual Care
Study: NCT00739648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376
Description: MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same frequency as study drug using the same method of delivery
Study: NCT04623931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01028014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: Cyclobenzaprine 10mg daily by mouth for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose capsule
Description: Lactose capsule 1 by mouth daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Solifenacin 5mg by mouth daily for 2 weeks
Study: NCT00640913

Intervention type: PROCEDURE
Intervention: Reversal of defunctioning stoma
Description: Reversal of defunctioning stoma
Study: NCT03465059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A single oral dose of 80 mg Zanubrutinib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A single oral dose of 80 mg Zanubrutinib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A single oral dose of 80 mg Zanubrutinib will be administered.
Study: NCT04623931

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT01815749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02068573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ventilation
Description: The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
Study: NCT04280445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Description: Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
Study: NCT01889953

Intervention type: OTHER
Group type: OTHER
Intervention: EUS-guided biliary drainage
Description: Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach
Study: NCT02716974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5mg by intramuscular (IM) injection every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: bicalutamide (Casodex) 50mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
Study: NCT03465059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A single oral dose of 80 mg Zanubrutinib will be administered.
Study: NCT05623540

Intervention type: DRUG
Intervention: Bisphosphonates, Combinations
Study: NCT02716974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Removal of the entire prostate gland, plus some surrounding tissue.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
Study: NCT03603665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1633
Description: NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1633
Description: NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1633
Description: NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
Study: NCT01786512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F1 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F1 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F1 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F1 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F2 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Matrix F2 Formulation
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified release tablets matching to omecamtiv mecarbil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified release tablets matching to omecamtiv mecarbil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified release tablets matching to omecamtiv mecarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Swellable Core Technology F2
Description: Modified release tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil Swellable Core Technology F2
Description: Modified release tablets for oral administration
Study: NCT03735329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test of SPO2
Description: The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
Study: NCT02469493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture (Huatuo)
Description: The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture (Huatuo)
Description: The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
Study: NCT02898350

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser treatment
Description: Scar minimization with Pulsed dye laser treatment on suture removal day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser treatment
Description: Scar minimization with CO2 laser treatment on suture removal day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined PDL and CO2 laser treatment
Description: Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split PDL and CO2 Laser treatment
Description: Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
Study: NCT03149887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine solution (Exparel) for injection
Study: NCT02764281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDA
Description: Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Description: Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
Study: NCT02165280

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided IMagery (GIM)
Description: It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
Study: NCT01616238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Study: NCT02068508

Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone Tablets